CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Protagenic Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Protagenic Therapeutics Inc
149 FIFTH AVENUE, SUITE 500
Phone: (212) 994-8200p:212 994-8200 NEW YORK, NY  10010  United States Ticker: PTIXPTIX
Business Summary
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes--

Industries
SIC Code Description
7389 Business services, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Garo H.Armen 70 2/12/2016 2/12/2016
Chief Financial Officer Alexander K.Arrow 53 1/1/2022 2/12/2016
Chief Operating Officer AndrewSlee 73 4/1/2016 4/1/2016
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Traffix, Inc. One Blue Hill Plaza Pearl River NY United States

Business Names
Business Name
ATRN
ATRND
Protagenic Therapuetics Canada
PTIX

General Information
Number of Employees: 41 (As of 12/31/2010)
Outstanding Shares: 4,435,132 (As of 3/29/2024)
Shareholders: 3,000
Stock Exchange: NASD
Federal Tax Id: 341775913
Fax Number: (302) 636-5454
Email Address: MILBROOKNY@AOL.COM


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024